• In March 2026, Ascendis Pharma reported positive new data for its TransCon portfolio, including Week 52 Phase 2 results for TransCon hGH in Turner syndrome and two-year ApproaCH Trial outcomes for TransCon CNP in achondroplasia, while also adding former BioMarin CEO Jean‑Jacques Bienaimé to its board as a non‑executive director.
• The combination of once‑weekly therapies showing efficacy and safety comparable to existing daily standards, plus experienced rare‑disease leadership, highlights Ascendis’s push to strengthen its position in growth‑disorder treatments.
• We’ll now explore how these TransCon hGH and YUVIWEL data updates may influence Ascendis Pharma’s investment narrative and long‑term outlook.

AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Ascendis Pharma Investment Narrative Recap

To own Ascendis Pharma, you need to believe its TransCon platform can turn a small set of rare endocrine drugs into a durable, multi-indication franchise while controlling cash burn. Near term, the key catalyst is commercial execution for SKYTROFA, YORVIPATH and newly approved YUVIWEL, with the biggest risk still concentrated exposure to a few products and ongoing losses; the latest TransCon hGH and TransCon CNP data support the growth-disorder story but do not remove that concentration risk.

The most relevant update here is the new Week 104 ApproaCH data for TransCon CNP and the recent US FDA approval of YUVIWEL for achondroplasia. This moves TransCon CNP from a pipeline narrative into an in-market asset with emerging long term data, directly linked to future label decisions and payer discussions that could influence how much YUVIWEL really offsets Ascendis’s heavy dependence on SKYTROFA and YORVIPATH.

Yet even with encouraging once weekly data and a rare disease veteran joining the board, investors should still be aware that Ascendis’s reliance on a handful of TransCon products...

Ascendis Pharma's narrative projects €2.2 billion revenue and €826.6 million earnings by 2028. This requires 63.9% yearly revenue growth and a €1.1 billion earnings increase from €-271.2 million today.

Uncover how Ascendis Pharma's forecasts yield a $286.75 fair value, a 32% upside to its current price.

Exploring Other Perspectives

Before this news, the most optimistic analysts were already banking on about €2.9 billion of revenue and €1.6 billion of earnings by 2029, so if you think recent TransCon data softens the concentration risk they highlight, you may see their outlook as far more optimistic than the baseline view and worth comparing with your own expectations.

Explore 4 other fair value estimates on Ascendis Pharma - why the stock might be worth over 3x more than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Ascendis Pharma research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Ascendis Pharma research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Ascendis Pharma's overall financial health at a glance.

Searching For A Fresh Perspective?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Find 62 companies with promising cash flow potential yet trading below their fair value.
• This technology could replace computers: discover 22 stocks that are working to make quantum computing a reality.
• Uncover the next big thing with 32 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.